Germline Mutations in Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Genetics
• Cancer Research

Background:

• Triple-negative breast cancer (TNBC) has a poor prognosis and lacks targeted therapies.
• TNBC is a heterogeneous disease requiring further subtyping for effective treatment.
• Hereditary factors are strongly implicated in TNBC, with a significant proportion of patients having a family history.

Purpose of the Study:

• To review the role of germline mutational status in the pathogenesis of TNBC.
• To highlight the predictive value of germline mutations for therapy response in TNBC.
• To discuss clinical trials involving BRCA1/2 mutation carriers with TNBC.

Main Methods:

• Literature review summarizing current research on germline mutations in TNBC.
• Analysis of the prevalence of pathogenic germline mutations, including BRCA1/2, PALB2, and FANCM.
• Discussion of clinical trial data related to BRCA1/2 mutation carriers.

Main Results:

• Pathogenic germline BRCA1/2 mutations are found in approximately twice the rate in TNBC compared to breast cancer overall.
• Early onset and positive family history are significant predictors of BRCA1/2 mutations in TNBC, reaching up to 40% probability.
• Other genes like PALB2 and FANCM are also associated with TNBC predisposition.

Conclusions:

• Germline mutational status is a critical biomarker for understanding TNBC pathogenesis and predicting treatment response.
• Targeted therapies, especially those affecting DNA repair, show promise for TNBC patients with specific germline mutations.
• Further subtyping of TNBC based on genetic markers is essential for developing personalized therapeutic strategies.